Blood 136 , 9891001 (2020)

Disclosures: Alina Jucov: Nothing to Disclose, Edward Gane: Nothing to Disclose, Man-Fung Yuen: Nothing to Disclose, Kosh Agarwal: Nothing to Disclose, Anca Streinu-Cercel: Nothing to Disclose, Young-Suk Lim: Nothing to Disclose, Keith Boundy: Nothing to Disclose, Cara Pilowa: Nothing to Disclose, Michael Chattergoon: Nothing to Disclose, Andre Arizpe: Vir Biotechnology: Employee, Vir Biotechnology: Stock - publicly traded company, Vaidehi Thanawala: Nothing to Disclose, Shuli Yu: Nothing to Disclose, Pan Wu: Nothing to Disclose, Yimeng Lu: Nothing to Disclose, Todd Correll: Nothing to Disclose, Tarik Asselah: Nothing to Disclose 417 THE IMPACT OF STEATOTIC LIVER DISEASE ON HBV INTEGRATION IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION Zhiwei Chen 1 Yan Han 1 Na Wu 1 Jing Tang 1 Peng Hu 1 Hong Ren 1 , 1 Second Affiliated Hospital of Chongqing Medical University Background: Steatotic liver disease (SLD) was associated with an increased risk of HCC among patients with chronic hepatitis B virus infection (CHB) but with a higher chance of achieving an HBsAg loss

Os principais mecanismos descritos na literatura cientfica incluem: 1
Adv Healthc Mater A Self-Assembled Transdermal Nanomedicines Incorporating Pendant Disulfides for Non-Invasive, Synergistic Treatment of Melanoma